DavidSchiffMD

Neurology • Charlottesville, VA

Neurooncology

Harrison Distinguished Teaching Professor of Neurology, University of Virginia School of Medicine

Join to view full profile

Dr. Schiff is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schiff's full profile

Already have an account?

Office
1240 Lee St
Fl 3
Charlottesville, VA 22908
Phone+1 434-924-9333

Fax+1 434-982-4467

Education & Training

Brigham and Women's HospitalInternship, Internal Medicine, 1988 - 1989
Harvard Medical SchoolClass of 1988

Certifications & Licensure

AZ State Medical License 1996 - Present
VA State Medical License 2001 - 2026
PA State Medical License 1996 - 2002
MN State Medical License 1993 - 1997
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
CMS Meaningful Use Stage 1 Certification EpicCare Inpatient - Core EMR, Epic Systems Corporation, 2012

Clinical Trials

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Start of enrollment: 2003 Jun 01
Completed
Phase 1, Phase 2
Everolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2009 Mar 01
Completed
Phase 1, Phase 2
A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma Start of enrollment: 2008 Aug 01
Unknown status
Phase 1, Phase 2
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Start of enrollment: 2009 Jun 01
Completed
Phase 3
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma Start of enrollment: 2009 Nov 17
Active, not recruiting
Phase 3
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Start of enrollment: 2012 Nov 01
Completed
Phase 1, Phase 2
ANG1005 in Patients With Recurrent High-Grade Glioma Start of enrollment: 2013 Oct 01
Completed
Phase 2
Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma Start of enrollment: 2019 Jun 17
Recruiting
Phase 1, Phase 2
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma Start of enrollment: 2019 Jul 30
Recruiting
Phase 2, Phase 3
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) Start of enrollment: 2017 Feb 09
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Primary diffuse leptomeningeal glioblastoma: a case report and literature review.
Mark Willy L Mondia, Rebekka E Hooks, Georgios A Maragkos, Vanessa L Smith, Matthew R McCord
Journal of Neuro-Oncology. 2025-03-01
2 citations
ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2025-02-20
Benchmarking the Efficacy of Salvage Systemic Therapies for Recurrent Meningioma: A RANO Group Systematic Review and Meta-analysis to Guide Clinical Trial Design.
Rupesh Kotecha, Eyub Y Akdemir, Tugce Kutuk, Can Ilgin, Manmeet S Ahluwalia
Neuro-Oncology. 2025-01-14

Journal Articles

Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal Lymphoma
Lisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood

Other

Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
David Schiff, MD, Clinical Cancer Research
https://www.doximity.com/articles/e5ba8350-d6fc-4d24-833f-8632cfbcc6e1
UpToDate, Wolters Kluwer Health - 2012-10-03
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
David Schiff, MD, Clinical Cancer Research
https://www.doximity.com/articles/e5ba8350-d6fc-4d24-833f-8632cfbcc6e1
UpToDate, Wolters Kluwer Health - 2012-04-09
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
David Schiff, MD, Clinical Cancer Research
https://www.doximity.com/articles/e5ba8350-d6fc-4d24-833f-8632cfbcc6e1
UpToDate, Wolters Kluwer Health - 2012-08-28
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
David Schiff, MD, Clinical Cancer Research
https://www.doximity.com/articles/e5ba8350-d6fc-4d24-833f-8632cfbcc6e1
UpToDate, Wolters Kluwer Health - 2012-07-30
Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma
David Schiff, MD, Clinical Cancer Research
https://www.doximity.com/articles/e5ba8350-d6fc-4d24-833f-8632cfbcc6e1
UpToDate, Wolters Kluwer Health - 2012-12-20
Join now to see all

Press Mentions

Trial Identifies Better Treatment for Grade 2 GliomasDecember 3rd, 2024
Adding Temozolomide to Radiation Therapy May Improve Survival in Adults with Low-Grade GliomasNovember 26th, 2024
New Brain Cancer Guidelines to Improve Care, Patient SurvivalJanuary 26th, 2022